Lobo is a former executive of Johnson & Johnson, where over the span of nearly a decade, he held a number of leadership roles. Most recently, Lobo was the worldwide president of Ethicon Endo Surgery, a $4 billion division of J&J. He also served as vice president of finance for the McNeil Consumer & Specialty Pharmaceuticals as well as Women’s Health & Urology; in addition, he was general manager for the McNeil Consumer Healthcare business in Canada.
Those businesses grew to $3.7 billion in revenue during his tenure.
“The creation of our new Neurotechnology and Spine Group will enable us to bring stronger alignment to these exciting market segments, and better serve the evolving needs of our surgeon customers in these areas,” said Stephen P. Macmillian, Stryker’s chairman, president and CEO. “Kevin’s record of delivering business results, his strong customer focus and his global leadership abilities are ideally suited for ensuring we capitalize on the many opportunities the neurotechnology and spine markets present our organization.”
Lobo assumed responsibility for the Spine division on June 1 and will add the Neurovascular division to his official duties on August 1. He has a bachelor’s degree in commerce from McGill University in Montreal, Canada, and a master’s degree in business administration from the University of Toronto in Canada.
Stryker is based in Kalamazoo, Mich.
Structural Changes Announced at RTI Biologics
RTI Biologics Inc. has instituted some structural changes. The company has separated the roles of board chairman and CEO, and named Dean H. Bergy board chairman. Brian K. Hutchison, who has been chairman and and CEO since 2001, will retain his CEO title but also will serve on the board of directors.
Bergy has been an advisor to the chief financial officer at Stryker Corp. since April 2009. He joined Stryker in 1994, and previously was the company’s vice president and CFO, as well as vice president of finance and chief accounting officer for Stryker’s medical division. Prior to his tenure with Stryker, Bergy worked with Ernst & Young and PricewaterhouseCoopers LLP.
“Dean is an exceptional executive and has deep experience with the intricacies of the healthcare and medical device industries,” Hutchison said. “We are very pleased he has agreed to take on the role of chairman.”
Besides separating the roles of CEO and board chairman, RTI Biologics has eliminated the position of Lead Director and given the duties formerly performed by Peter F. Gearen, M.D., to Bergy. Gearen, however, will remain on the board of directors.
RTI is based in Alachua, Fla.
Globus Medical Names New Member of Board of Directors
Daniel T. Lemaitre has been named to the board of directors at Globus Medical Inc.
Lemaitre currently is president and CEO of White Pine Medical. He also serves on the board of Irvine, Calif.-based Endologix, Inc., and is a trustee for the Lawrence Academy in Groton, Mass. He previously was president and CEO of CoreValve, where he is credited with company growth and orchestrating its sale to Medtronic Inc. in February 2009. Prior to joining CoreValve, Lemaitre was senior vice president of strategy and corporate development at Medtronic. He also has 29 years of experience as an investment analyst of medical devices.
“The appointment of Dan to the board of directors will help to continue Globus’ momentum towards our goal of becoming the preeminent spine company,” David Paul, chairman and CEO of Globus Medical, said.
Globus Medical is a privately held spinal implant manufacturer headquartered in Audobon, Pa.
Comings and Goings at Small Bone Innovations
Richard L. Kovach has joined Small Bone Innovations Inc. (SBi) as senior vice president. Kovach will be responsible for worldwide product management, product development, medical education, clinical, regulatory, reimbursement and intellectual property management. He will report to Anthony G. Viscogliosi, chairman and CEO.
“Rick possesses an excellent combination of skills and experience that will add immense value to our company and inject further momentum in building on our top position in the total ankle replacement marketplace, as well as our other small bone and joint arthroplasty product offerings,”Viscogliosi said in prepared remarks.
Before he was hired at (SBi), Kovach was president and chief operations officer at OrthoHelix Surgical Designs Inc., a Medina, Ohio-based provider of extremity fixation products.
The addition of Kovach is tempered by the departures of two senior SBi executives—Thomas A. Crowley, Jr., president; and Florian Kemmerich, president, SBi International SAS. Crowley, who left to focus on his role as board director of several charitable organizations, is providing consulting services to SBi. Kemmerich, on the other hand, accepted a position leading Olympus Biotech Europe SAS.
SBi was founded in 2004 by Viscogliosi Brothers, LLC, a venture capital/private equity and merchant banking firm. Headquartered in New York, N.Y., the company has facilities in Morrisville, Pa.; Bourg-en-Bresse, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia.
Two New Leaders Join Ortho Kinematics
Ortho Kinematics has announced the additions of David Muller as vice president of sales and Ken Walker, R.N., as director of clinical operations.
Muller has held senior positions with both start-up and major spine industry manufacturers in his 30-year tenure in the medical device industry.
Walker will oversee all aspects of the ongoing clinical study of the privately held company’s KineGraph VMA (Vertebral Motion Analyzer). Previously, he was director of the Zimmer Institute and global director of medical education for Abbott Spine, Inc.
“I am thrilled to have David Muller and Ken Walker join the team because they bring extensive experience in the spine industry and over the years have developed strong relationships with renowned spine surgeons,” Adam Deitz, CEO, said. “Their leadership skills will help drive Ortho Kinematics as we progress towards product commercialization. They both share our passion and vision for improving patient care through better spine motion diagnostics.”
Ortho Kinematics is a spine diagnostics company based in Austin, Texas.
Orthofix Names New CFO
Orthofix International N.V. has promoted Brian McCollum to chief financial officer. McCollum, who had been serving as interim CFO since Jan. 1, officially assumed his new role on March 1.
“We are delighted to promote Brian to the CFO position,” Alan Milinazzo, Orthofix president and CEO, said. “Throughout his 10-year tenure with Orthofix he has taken on roles of increasing responsibility, including successfully serving as the vice president of finance for our largest domestic and international business units which gives him tremendous insight into our business worldwide.”
Last year, executives named McCollum senior vice president of finance. He joined Orthofix’s corporate finance group in 2001, eventually advancing to the position of corporate controller. In 2006, McCollum was named vice president of finance, Americas, and two years later became vice president of international finance and group treasurer. Prior to joining Orthofix, McCollum was a senior audit associate with PricewaterhouseCoopers.
Orthofix is a global medical device company based in Curaco, Netherlands Antilles.
Orthocon Names New President and CEO
John J. Pacifico has been named president, CEO and a member of Orthocon Inc.’s board of directors. He joined the company in 2007 as vice president of corporate development, and was made senior vice president of commercial operations in 2009. Pacifico was responsible for the commercial launch of OrthoStat, the company’s first U.S. Food and Drug Administration-approved product, according to the company.
“John was the obvious best choice to lead this new era for the organization,” said Seth Rudnick, M.D., board chairman.
Founder and Principal Technology Inventor Richard L. Kronenthal, Ph.D., agreed: “Having worked with [Pacifico] for several years, I am convinced his business capabilities and entrepreneurial enthusiasm will provide strength and significant growth for our organization.”
Pacifico is a former member of the healthcare venture capital investment team at Canaan Partners, where he served as a leader and investor. During his time at the global firm, he established an extensive network of physicians, business leaders, service providers and investors, Orthocon executives said.
Pacifico said he is eager to help Orthocon develop and commercialize products.
“Orthocon represents an outstanding opportunity for me to build a leading therapeutic device company around a core team of people and a portfolio of products,” Pacifico said. “I am eager to lead Orthocon in its quest to continue to develop and commercialize products that address unmet needs in surgery and post-operative patient care.”
Founded in 2005, Orthocon is based in Irvington, N.Y. The company develops, manufactures, markets and sells products that stop bleeding from the bone and deliver drugs to the bone.